The allocation of resources for R&D in the world's leading pharmaceutical companies

R and D Management

Volumn 27, Issue 1, 1997, Pages 63-77

  Halliday, Richard G ^a   Drasdo, Alison L ^a   Lumley, Cyndy E ^a   Walker, Stuart R ^a  

^a Ctr for Medicines Res Intl   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002458231     PISSN: 00336807     EISSN: None     Source Type: Journal    
DOI: 10.1111/1467-9310.00042     Document Type: Article

References (24)

1. Anon (1991) Data Book 1991. Tokyo: Japan Pharmaceutical Manufacturers Association.
2. Anon (1993a) Pharmaceutical R&D: Costs, Risks and Rewards. Congress ofthe United States, Office of Technology Assessment, Washington DC: US Government Printing Office.
3. Anon (1993b) Scrip League Tables. Richmond: PJB Publications.
4. Anon (1993c) Intercontinental Medical Statistics (IMS). In The Pharmaceutical Market World Review. 1992 Vol. 1, International. London: IMS AG.
5. Anon (1993d) Data Book 1993. Tokyo: Pharmaceutical Manufacturers Association.
6. Anon (1994a) OECD Main Economic Indicators. Paris: Organisation for Economic Cooperation Development.
7. Anon (1994b) Pharmaceutical Industry in Japan 1994. Japan: Japan Pharmaceutical Manufacturers Association.
8. Barral, P. E. (1990) Fifteen years of pharmaceutical research results throughout the world (1975-1989). Paper presented at the 30th Colloquium on Applied Economy (AEA-GS-Health), Ankara, Turkey, June 28.
9. Beam, A. G. (1983) Academe, government and the pharmaceutical industry: a tripod of necessity. Prog. Clin. Biol. Res. 128, 27-34.
10. Cookson, C. (1991) On the backburner. Financial Times, October 17.
11. Craig, A. M. and Malek, M. (1995) Market structure and conduct in the pharmaceutical industry. Pharmac. Ther. 66, 301-337.
12. Donnelly, E. (1996) Company strategies to ensure a quick and efficient review: a transnational company. In Lumley, C. E. and Walker, S. R. (eds) Improving the Regulatory Review Process: Industry and Regulatory Initiatives. Lancaster: Kluwer Academic, 41-51.
13. Drews, J. (1995) The impact of cost containment on pharmaceutical research and development. Tenth CMR Annual Lecture, Carshalton: Centre for Medicines Research.
14. Halliday, R. G. (1996) Success in pharmaceutical R&D: the different strategies of Western and Japanese companies. Drug Information Journal, 30, 3, 821-837.
15. Halliday, R. G. Walker, S. R. and Lumley, C. E. (1992) R&D philosophy and management in the world's leading pharmaceutical companies. Journal of Pharmaceutical Medicine, 2, 139-154.
16. Kaitin, K. I. (1990) Impact of policy research on drug development strategies. Drug Information Journal, 24, 207-212.
17. Keegan, W. I. (1984) Chapter 1. In Hampton, G. M. and Van Gent, A. P. (eds) Marketing Aspects of International Business. Kluwer Academic.
18. Macarthur, D. (1991) Japanese business expansion into Europe. Financial Times Business Information.
19. MacFarlane, F. G., Kunze, Z. M., Drasdo, A. L., Lumley, C. E. and Walker, S. R. (1995) Trends in world-wide R&D expenditure 1981-1993. Journal of Pharmaceutical Medicine, 5, 17-31.
20. MacInnes, R., Lumley, C. E. and Walker, S. R. (1994) New chemical entity output of the international pharmaceutical industry from 1970 to 1992. Clinical Pharmacology and Therapeutics, 56, 3, 339-349.
21. MacInnes, R., MacFarlane, F. G., Drasdo, A. L. and Lumley, C. E. (1995) International drug development: efficiency and output (1980-1994). Carshalton: Centre for Medicines Research, CMR95-54R.
22. Omta, S. W. F., Bouter, L. M. and Engelen J. M. L. (1994) Managing industrial pharmaceutical R&D. A comparative study of management control and innovative effectiveness in European and Anglo-American companies. R&D Management, 24, 4, 303-315.
23. Thesig, J. (1984) Industrial Drug Research Today Mainz: Med.-Pharmazeut. Studienges.
24. Yano, Y. (1991) The competitiveness of the Japanese pharmaceutical industry in the 1990s. CMR News, 9, 3, December.